ARTICLE | Product R&D
Natural spots
HotSpot Therapeutics’ small molecules take a page from natural allostery
July 17, 2018 9:58 PM UTC
With a new take on allosteric modulation, HotSpot Therapeutics Inc. has emerged from stealth mode to find specialized niches on proteins that nature uses to control their activity. The company’s platform has identified druggable allosteric sites on more than 100 targets, including transcription factors and other proteins that lack active sites.
On July 17, HotSpot announced that it completed a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company plans to nominate two lead candidates by early next year. ...